NCT03724175View on ClinicalTrials.gov

The Role of Secondary Bile Acids in Intestinal Inflammation

PHASE2/PHASE3RecruitingINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

August 26, 2019

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2050

Conditions
Ulcerative ColitisPouchitis
Interventions
DRUG

ursodiol (ursodeoxycholic acid, UDCA)

ursodiol (ursodeoxycholic acid, UDCA) 300 mg two times daily for 10 weeks for UC pouchitis patients

Trial Locations (1)

94305

RECRUITING

Stanford University, Stanford

All Listed Sponsors
lead

Stanford University

OTHER